Agios Pharmaceuticals, Inc. (AGIO) PT Raised to $66.00

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) had its price target boosted by analysts at Credit Suisse Group from $61.00 to $66.00 in a note issued to investors on Thursday, November 2nd. The brokerage currently has an “outperform” rating on the biopharmaceutical company’s stock. Credit Suisse Group’s price objective indicates a potential upside of 11.00% from the company’s current price.

A number of other brokerages have also recently commented on AGIO. BidaskClub cut Agios Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, August 9th. SunTrust Banks, Inc. reaffirmed a “buy” rating and set a $80.00 price objective (up from $68.00) on shares of Agios Pharmaceuticals in a research note on Tuesday, August 8th. Needham & Company LLC lifted their price objective on Agios Pharmaceuticals from $54.00 to $72.00 and gave the stock a “buy” rating in a research note on Thursday, August 10th. Oppenheimer Holdings, Inc. reissued an “outperform” rating and issued a $83.00 target price (up from $75.00) on shares of Agios Pharmaceuticals in a research note on Thursday, August 10th. Finally, Leerink Swann raised Agios Pharmaceuticals from a “market perform” rating to an “outperform” rating and boosted their target price for the company from $50.00 to $80.00 in a research note on Wednesday, August 2nd. Three investment analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. The company currently has an average rating of “Buy” and a consensus target price of $75.70.

Agios Pharmaceuticals (NASDAQ:AGIO) opened at $59.46 on Thursday. Agios Pharmaceuticals has a 52-week low of $39.24 and a 52-week high of $72.73.

Agios Pharmaceuticals (NASDAQ:AGIO) last issued its quarterly earnings data on Wednesday, November 1st. The biopharmaceutical company reported ($1.59) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.78) by $0.19. The firm had revenue of $11.35 million during the quarter, compared to the consensus estimate of $10.85 million. Agios Pharmaceuticals had a negative return on equity of 69.64% and a negative net margin of 506.39%. The business’s revenue for the quarter was up 26.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($1.63) EPS. equities analysts predict that Agios Pharmaceuticals will post -6.59 EPS for the current year.

WARNING: This report was originally reported by Week Herald and is the property of of Week Herald. If you are reading this report on another publication, it was illegally stolen and republished in violation of U.S. & international copyright legislation. The original version of this report can be read at https://weekherald.com/2017/11/15/agios-pharmaceuticals-inc-agio-pt-raised-to-66-00.html.

In other news, CEO David P. Schenkein sold 6,000 shares of the stock in a transaction on Friday, September 1st. The stock was sold at an average price of $62.20, for a total value of $373,200.00. Following the completion of the transaction, the chief executive officer now directly owns 6,000 shares in the company, valued at approximately $373,200. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Lewis Clayton Jr. Cantley sold 4,000 shares of the stock in a transaction on Tuesday, October 17th. The shares were sold at an average price of $71.10, for a total value of $284,400.00. Following the completion of the transaction, the director now owns 84,394 shares of the company’s stock, valued at $6,000,413.40. The disclosure for this sale can be found here. Insiders sold 178,908 shares of company stock worth $12,147,719 in the last ninety days. 10.55% of the stock is owned by company insiders.

A number of large investors have recently made changes to their positions in AGIO. BlackRock Inc. raised its position in Agios Pharmaceuticals by 8,463.5% during the 1st quarter. BlackRock Inc. now owns 2,167,074 shares of the biopharmaceutical company’s stock worth $126,556,000 after purchasing an additional 2,141,768 shares during the last quarter. FMR LLC raised its position in shares of Agios Pharmaceuticals by 14.1% in the 2nd quarter. FMR LLC now owns 7,227,331 shares of the biopharmaceutical company’s stock worth $371,846,000 after acquiring an additional 895,584 shares in the last quarter. Vanguard Group Inc. raised its position in shares of Agios Pharmaceuticals by 23.8% in the 2nd quarter. Vanguard Group Inc. now owns 3,214,770 shares of the biopharmaceutical company’s stock worth $165,401,000 after acquiring an additional 617,379 shares in the last quarter. Goldman Sachs Group Inc. raised its position in shares of Agios Pharmaceuticals by 748.0% in the 1st quarter. Goldman Sachs Group Inc. now owns 649,124 shares of the biopharmaceutical company’s stock worth $37,909,000 after acquiring an additional 572,579 shares in the last quarter. Finally, Janus Henderson Group PLC bought a new position in shares of Agios Pharmaceuticals in the 2nd quarter worth about $20,423,000. 93.16% of the stock is owned by institutional investors and hedge funds.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company’s cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2.

Analyst Recommendations for Agios Pharmaceuticals (NASDAQ:AGIO)

Receive News & Ratings for Agios Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply